- Question from Dorcas: Dr. Kaplan, was there any news about upcoming clinical trials at the meeting? What trials are you working on?
- Answers - Carol Kaplan Yes, there are a multitude of clinical trials ongoing internationally meant to address many of the questions remaining in the realms of metastatic and adjuvant therapy. Some of the most exciting trials in my opinion include the use of bevacizumab (brand name: Avastin). Bevacizumab is being investigated in combination with chemotherapy in the adjuvant setting after having shown clear benefit in trials previously reported in the metastatic setting. Other notable ongoing trials include those making use of the previously mentioned PARP inhibitors, both as monotherapy and in combination with chemotherapeutic agents.
- Ruth Oratz, M.D., F.A.C.P. I think what's exciting and promising, and what we saw at this meeting, was that research was proceeding at a fast pace. There is a great deal of interest in defining not only the underlying biological mechanisms of the disease, but in identifying a variety of new therapeutic approaches.
- Carol Kaplan For patients interested in seeking out clinical trials for which they may be eligible, www.clinicaltrials.gov is an excellent Web site that allows you to search for open clinical trials and future clinical trials that may be relevant to your care.
On Wednesday, December 17, 2008, our Ask-the-Expert Online Conference was called Updates from the 2008 San Antonio Breast Cancer Symposium. Ruth Oratz, M.D., F.A.C.P. and Carol Kaplan, M.D. answered your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.